Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd.

TTPEX:6576
70.60
TWD
-0.90
(-1.26%)
0.14EPS
561.91P/E
12.73BMarket Cap

Total Valuation

TWD

As of June 30, 2026, Foresee Pharmaceuticals Co., Ltd. carries a market capitalization of 12.73B, placing it among publicly traded companies globally. Its enterprise value stands at 12.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.73B
Enterprise Value12.22B

Important Dates

Foresee Pharmaceuticals Co., Ltd.'s next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of June 30, 2026, Foresee Pharmaceuticals Co., Ltd. has 157.54M shares outstanding.

Shares Outstanding157.54M

Valuation Ratios

As of June 30, 2026, Foresee Pharmaceuticals Co., Ltd. trades at a trailing price-to-earnings ratio of 561.91. The price-to-sales ratio is 26.83, and the price-to-book ratio stands at 10.00.

PE Ratio561.91
PS Ratio26.83
PB Ratio10.00
P/TBV Ratio10.87
P/FCF Ratio-21.09
P/OCF Ratio-23.19

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 25.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.22B versus a market cap of 12.73B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales25.93

Financial Position

As of June 30, 2026, Foresee Pharmaceuticals Co., Ltd. maintains a current ratio of 8.98, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.29, indicating elevated leverage, while an interest coverage ratio of -51.90 demonstrates limited ability to service its debt obligations.

Current Ratio8.98
Quick Ratio7.07
Debt / Equity31.29
Debt / EBITDA-0.91
Interest Coverage-51.90

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Foresee Pharmaceuticals Co., Ltd. posted a return on equity (ROE) of 2.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -8.52, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.31, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.70, useful for judging operating efficiency across full business cycles. The company generates approximately 11.49M in revenue per employee across its workforce of 41.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.69 indicates how many times Foresee Pharmaceuticals Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)2.00
Return on Assets (ROA)1.31
Return on Invested Capital (ROIC)-8.52
Return on Capital Employed (ROCE)1.70
Revenue Per Employee11.49M
Employee Count41.00
Inventory Turnover0.69

Taxes

TWD

Over the twelve months ended June 30, 2026, Foresee Pharmaceuticals Co., Ltd. recorded 66.76M in income tax expense. That works out to an effective tax rate of 74.79, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 89.25M, leaving 22.50M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax66.76M
Effective Tax Rate74.79

Stock Price Statistics

TWD

As of the close on November 17, 2026, Foresee Pharmaceuticals Co., Ltd.'s stock has declined approximately 12.41% over the past 52 weeks. The 50-day moving average sits at 77.77, while the 200-day moving average is 79.53.

52-Week Price Change-12.41%
50-Day Moving Average77.77
200-Day Moving Average79.53

Income Statement

TWD

Over the twelve months ended June 30, 2026, Foresee Pharmaceuticals Co., Ltd. generated 471.13M in revenue and converted that into 22.50M in net income, yielding earnings per share of 0.14. EBITDA reached -436.13M, while operating income came in at -492.31M.

Revenue471.13M
Gross Profit366.08M
Operating Income-492.31M
Pretax Income89.25M
Net Income22.50M
EBITDA-436.13M
EBIT-492.31M
Earnings Per Share (EPS)0.14

Balance Sheet

TWD

As of June 30, 2026, Foresee Pharmaceuticals Co., Ltd. holds 910.92M in cash and equivalents against 398.33M in total debt, resulting in a net debt position of -506.90M. Total book value stands at 1.27B, with working capital of 1.03B providing operational flexibility.

Cash & Cash Equivalents910.92M
Total Debt398.33M
Net Debt-506.90M
Equity (Book Value)1.27B
Book Value Per Share8.08
Working Capital1.03B

Cash Flow

TWD

Foresee Pharmaceuticals Co., Ltd. produced -545.15M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -54.71M in capital expenditures, free cash flow totaled -599.86M - equivalent to -3.83 per share.

Operating Cash Flow-545.15M
Capital Expenditures-54.71M
Free Cash Flow-599.86M
FCF Per Share-3.83

Margins

Over the twelve months ended June 30, 2026, Foresee Pharmaceuticals Co., Ltd. posted a gross margin of 77.70, reflecting its pricing power and cost economics. The operating margin of -104.50 and net profit margin of 4.77 provide insight into operational efficiency.

Gross Margin77.70
Operating Margin-104.50
Pretax Margin18.94
Profit Margin4.77
EBITDA Margin-92.57

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.74: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.74, meaning Foresee Pharmaceuticals Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-2.74
FCF Yield-4.74

Stock Splits

Foresee Pharmaceuticals Co., Ltd.'s most recent stock split took place on June 1, 2023 with a 809:818 split ratio.

Last Split Date6/1/2023
Split Ratio809:818

Scores

As of June 30, 2026, Foresee Pharmaceuticals Co., Ltd. has an Altman Z-Score of 7.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.98